Pamatolol
| Pamatolol | |
|---|---|
| Pamatolol.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pamatolol is a beta-adrenergic blocking agent (beta-blocker) used in the management of various cardiovascular conditions. It is known for its ability to reduce heart rate, blood pressure, and myocardial oxygen demand by blocking the action of epinephrine and norepinephrine on beta-adrenergic receptors.
Pharmacology[edit]
Pamatolol is a non-selective beta-blocker, meaning it inhibits both beta-1 and beta-2 adrenergic receptors. This action results in decreased cardiac output and peripheral resistance, which contributes to its antihypertensive effects.
Mechanism of Action[edit]
Pamatolol works by competitively blocking the beta-adrenergic receptors in the heart and vascular smooth muscle. This blockade prevents the usual sympathetic nervous system response, leading to a decrease in heart rate and contractility, as well as vasodilation.
Clinical Uses[edit]
Pamatolol is primarily used in the treatment of hypertension, angina pectoris, and certain types of arrhythmia. It may also be used in the management of myocardial infarction to reduce mortality and improve outcomes.
Side Effects[edit]
Common side effects of Pamatolol include bradycardia, fatigue, dizziness, and gastrointestinal disturbances. As with other beta-blockers, it may exacerbate symptoms of asthma and chronic obstructive pulmonary disease (COPD) due to its non-selective action.
Contraindications[edit]
Pamatolol is contraindicated in patients with asthma, severe bradycardia, heart block, and cardiogenic shock. Caution is advised in patients with diabetes mellitus as it may mask hypoglycemic symptoms.
